Skip to main content

Semaglutide Beneficial for Hidradenitis Suppurativa in Patients With Obesity

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 25, 2024.

via HealthDay

WEDNESDAY, Sept. 25, 2024 -- For patients with obesity, the addition of semaglutide to standard hidradenitis suppurativa (HS) treatments yields improvement in quality of life and a reduction in flares, according to a study presented at the annual meeting of the European Academy of Dermatology and Venereology, held from Sept. 25 to 28 in Amsterdam.

Daniel Lyons, M.D., from St. Vincent's University Hospital in Dublin, and colleagues reported the impact of semaglutide on disease control and quality of life among 30 patients with obesity (27 female and three male) from an HS clinic.

All of the patients were prescribed concomitant HS treatments. The researchers found that the mean duration of semaglutide treatment was 8.2 months and the mean dose was 0.8 mg once weekly. There was a decrease seen in mean body mass index, from 43.1 to 41.5 kg/m2. In addition, the mean weight decreased from 117.7 to 111.6 kg. Overall, 33.33 percent of the patients lost ≥10 kg during the study period. The mean frequency of patient-reported flares decreased from once every 8.5 weeks to once every 12 weeks following commencement of semaglutide, with a reduction in the mean Dermatology Life Quality Index (DLQI) from 13/30 to 9/30. A DLQI reduction of 4 points or more, equal to or surpassing the minimal clinically important difference, occurred in one-third of patients. There was also a significant reduction in hemoglobin A1c (from 39.3 to 36.6).

"We hope our preliminary data will encourage dermatologists to consider weight loss medication as an adjunct to existing HS treatments," Lyons said in a statement.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

ENDO: Superior Weight Loss Seen With Tirzepatide and Menopausal Hormone Therapy Use

TUESDAY, July 15, 2025 -- In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is associated with superior weight loss...

Certain Factors May Predict Weight Fluctuations After GLP-1 Receptor Agonist Treatment

TUESDAY, July 15, 2025 -- For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs)...

ENDO: 1999 to 2020 Saw Significant Uptick in Obesity-Related Cancer Deaths

MONDAY, July 14, 2025 -- From 1999 to 2020, obesity-related cancer mortality increased significantly, according to a study presented at ENDO 2025, the annual meeting of the...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.